日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Development of intravenously administered synthetic RNA virus immunotherapy for the treatment of cancer

开发用于治疗癌症的静脉注射合成RNA病毒免疫疗法

Edward M Kennedy ,Agnieszka Denslow ,Jacqueline Hewett ,Lingxin Kong ,Ana De Almeida ,Jeffrey D Bryant ,Jennifer S Lee ,Judy Jacques ,Sonia Feau ,Melissa Hayes ,Elizabeth L McMichael ,Daniel Wambua ,Terry Farkaly ,Amal A Rahmeh ,Lauren Herschelman ,Danielle Douglas ,Jacob Spinale ,Sanmit Adhikari ,Jessica Deterling ,Matt Scott ,Brian B Haines ,Mitchell H Finer ,Ted T Ashburn ,Christophe Quéva ,Lorena Lerner

Design of an Interferon-Resistant Oncolytic HSV-1 Incorporating Redundant Safety Modalities for Improved Tolerability

设计干扰素耐药溶瘤 HSV-1,结合冗余安全模式以提高耐受性

Edward M Kennedy, Terry Farkaly, Peter Grzesik, Jennifer Lee, Agnieszka Denslow, Jacqueline Hewett, Jeffrey Bryant, Prajna Behara, Caitlin Goshert, Daniel Wambua, Ana De Almeida, Judith Jacques, Damian Deavall, James B Rottman, Joseph C Glorioso, Mitchell H Finer, Brian B Haines, Christophe Quéva, L

Phosphatidic Acid (PA) can Displace PPARα/LXRα Binding to The EGFR Promoter Causing its Transrepression in Luminal Cancer Cells

磷脂酸(PA)可取代PPARα/LXRα与EGFR启动子的结合,从而导致管腔癌细胞中EGFR的转录抑制。

Mahankali, Madhu; Farkaly, Terry; Bedi, Shimpi; Hostetler, Heather A; Gomez-Cambronero, Julian

Cell invasion of highly metastatic MTLn3 cancer cells is dependent on phospholipase D2 (PLD2) and Janus kinase 3 (JAK3)

高转移性MTLn3癌细胞的细胞侵袭依赖于磷脂酶D2(PLD2)和Janus激酶3(JAK3)。

Henkels, Karen M; Farkaly, Terry; Mahankali, Madhu; Segall, Jeffrey E; Gomez-Cambronero, Julian